While HPV vaccines will save lives, target schoolgirls will be hard to reach.
South Africa will become the first African country to pay for cervical cancer vaccines – one of the most expensive immunisations in the world – for schoolgirls in February next year. But experts warn that the health department will face daunting challenges, much bigger than the exorbitant cost of the vaccine.
Cervical cancer, which is caused by the sexually transmitted human papilloma virus (HPV), kills more South African women than any other cancer, according to the Medical Research Council. Every year about 6000 women, many of whom are HIV positive, are diagnosed with HPV, and at least half die.
One-year contract appointment with possible extension
This report presents the methods and findings of a qualitative study of the experiences of patients taking medication for HIV infection as part of an antiretroviral therapy (ART) programme in five sites in KwaZulu-Natal (KZN), South Africa. The study, known as the ADHERE Project, was designed by MEASURE Evaluation and implemented in collaboration with Health Systems Trust to provide information to the KwaZulu-Natal Department of Health for use in expanding and improving their ART services.